Thau Manh Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thau Manh Cao has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Hang Thi Thu Nguyen
Department of Oncology and Radiotherapy, Viet Duc University Hospital, Hanoi, Vietnam
3 shared publications - Lam Thanh Phan
Department of Oncology and Radiotherapy, Viet Duc University Hospital, Hanoi, Vietnam
3 shared publications - Trung Nghia Bui
Department of Oncology and Radiotherapy, Viet Duc University Hospital, Hanoi, Vietnam
3 shared publications Anh Gia Pham
2 shared publications- Anh Pham Gia
Department of Oncology and Radiotherapy, Viet Duc University Hospital, Hanoi, Vietnam
2 shared publications Cong Tien Bui
2 shared publications
Latest Publications
- Open Access
- 1 August 2026
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 13, 1-12
Outcomes of Preoperative TACE vs Upfront Hepatectomy in Hepatocellular Carcinoma: A Single-Center Retrospective Study in Vietnam
Purpose: This propensity score-matched study aimed to compare survival outcomes between preoperative TACE followed by hepatectomy and upfront hepatectomy in patients with resectable hepatocellular carcinoma. Patients and Methods: In this single-center retrospective cohort study at Viet Duc University Hospital, 304 consecutive patients with resectable HCC treated between January 2015 and October 2024 were analyzed: 168 underwent upfront hepatectomy and 136 received preoperative TACE followed by hepatectomy. Propensity score matching (PSM; 1:1 nearest-neighbor, caliper 0.01) was performed to balance pre-treatment covariates between groups. Overall survival (OS) and disease-free survival (DFS) were compared using Kaplan–Meier analysis and the Log rank test. Independent prognostic factors were identified using multivariable Cox regression. Results: Median follow-up was 58.9 months. After PSM (113 matched pairs), median OS was not reached in the upfront hepatectomy group versus 62.5 months in the preoperative TACE group (P = 0.322), and median DFS was 32.0 versus 29.2 months (P = 0.056). In multivariable Cox analysis of the matched cohort, preoperative TACE was not independently associated with OS (HR 1.15, 95% CI 0.74– 1.79; P = 0.526) or DFS (HR 1.19, 95% CI 0.92– 1.75; P = 0.130), whereas advanced TNM stage (OS: HR 2.45, 95% CI 1.08– 5.52, P = 0.032; DFS: HR 2.26, 95% CI 1.14– 4.46, P = 0.019) and microvascular invasion (OS: HR 1.48, 95% CI 1.09– 2.40, P = 0.007; DFS: HR 1.52, 95% CI 1.01– 2.29, P = 0.035) remained independent prognostic factors. Within the TACE group, patients achieving complete pathological necrosis (n = 26) had OS and DFS comparable to upfront hepatectomy, whereas incomplete or partial necrosis was associated with significantly worse survival (P = 0.05 for OS and P = 0.01 for DFS). Conclusion: In this retrospective, propensity score-matched cohort, preoperative TACE was not associated with improved overall or disease-free survival in patients with resectable HCC and does not appear justified as a routine strategy in patients who are already surgical candidates. Because the analysis was retrospective and residual confounding cannot be excluded, these findings should be regarded as hypothesis-generating. Any role for preoperative TACE in selected settings, such as borderline resectability or when complete tumor necrosis is achieved, requires prospective confirmation.
- 1 August 2026
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 13, 1-12
Open AccessOutcomes of Preoperative TACE vs Upfront Hepatectomy in Hepatocellular Carcinoma: A Single-Center Retrospective Study in Vietnam
Purpose: This propensity score-matched study aimed to compare survival outcomes between preoperative TACE followed by hepatectomy and upfront hepatectomy in patients with resectable hepatocellular carcinoma. Patients and Methods: In this single-center retrospective cohort study at Viet Duc University Hospital, 304 consecutive patients with resectable HCC treated between January 2015 and October 2024 were analyzed: 168 underwent upfront hepatectomy and 136 received preoperative TACE followed by hepatectomy. Propensity score matching (PSM; 1:1 nearest-neighbor, caliper 0.01) was performed to balance pre-treatment covariates between groups. Overall survival (OS) and disease-free survival (DFS) were compared using Kaplan–Meier analysis and the Log rank test. Independent prognostic factors were identified using multivariable Cox regression. Results: Median follow-up was 58.9 months. After PSM (113 matched pairs), median OS was not reached in the upfront hepatectomy group versus 62.5 months in the preoperative TACE group (P = 0.322), and median DFS was 32.0 versus 29.2 months (P = 0.056). In multivariable Cox analysis of the matched cohort, preoperative TACE was not independently associated with OS (HR 1.15, 95% CI 0.74– 1.79; P = 0.526) or DFS (HR 1.19, 95% CI 0.92– 1.75; P = 0.130), whereas advanced TNM stage (OS: HR 2.45, 95% CI 1.08– 5.52, P = 0.032; DFS: HR 2.26, 95% CI 1.14– 4.46, P = 0.019) and microvascular invasion (OS: HR 1.48, 95% CI 1.09– 2.40, P = 0.007; DFS: HR 1.52, 95% CI 1.01– 2.29, P = 0.035) remained independent prognostic factors. Within the TACE group, patients achieving complete pathological necrosis (n = 26) had OS and DFS comparable to upfront hepatectomy, whereas incomplete or partial necrosis was associated with significantly worse survival (P = 0.05 for OS and P = 0.01 for DFS). Conclusion: In this retrospective, propensity score-matched cohort, preoperative TACE was not associated with improved overall or disease-free survival in patients with resectable HCC and does not appear justified as a routine strategy in patients who are already surgical candidates. Because the analysis was retrospective and residual confounding cannot be excluded, these findings should be regarded as hypothesis-generating. Any role for preoperative TACE in selected settings, such as borderline resectability or when complete tumor necrosis is achieved, requires prospective confirmation.
- Open Access
- 1 August 2026
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 18, 1-14
Prognostic Determinants of Disease-Free Survival After Curative Resection for Hepatocellular Carcinoma: A Retrospective Cohort Study
- 1 August 2026
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 18, 1-14
Open AccessPrognostic Determinants of Disease-Free Survival After Curative Resection for Hepatocellular Carcinoma: A Retrospective Cohort Study
- Open Access
- 7 May 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26
Integrated clinicopathological model versus TNM for predicting survival in resected hepatocellular carcinoma: a retrospective cohort study
Objective: To explore prognostic factors of postoperative hepatocellular carcinoma (HCC) and compare the prognostic performance of the tumor–node–metastasis (TNM) system with an integrated clinicopathological model. Methods: We conducted a cohort study evaluating 249 patients with HCC who underwent radical liver resection between January 2015 and December 2024. Overall survival (OS) was the primary endpoint. Independent prognostic factors were determined using the Cox proportional hazards model. Model performance was assessed using the correlation index (C-index) with bootstrap internal validation. Time-dependent receiver operating characteristic (ROC) curves, decision curve analysis (DCA), and calibration plots were used to assess discrimination, clinical utility, and agreement between predicted and observed outcomes. Results: In multivariable analysis, TNM stage, microvascular invasion (MVI), resection margin status, and albumin–bilirubin (ALBI) grade were independent predictors of OS. For recurrence-free survival (RFS), independent predictors included hepatitis status, ALBI grade, TNM stage, and MVI. The integrated model demonstrated improved discrimination compared with TNM alone, with a higher optimism-corrected C-index (0.676 vs. 0.647). Time-dependent ROC analysis showed significantly higher AUC values for the integrated model at 1 year (0.725 vs. 0.669, p = 0.046), 3 years (0.703 vs. 0.657, p = 0.024), and 5 years (0.684 vs. 0.649, p = 0.031). DCA indicated greater net benefit across clinically relevant thresholds, and calibration plots showed good agreement between predicted and observed survival probabilities. Conclusion: An integrated clinicopathological model incorporating TNM stage, MVI, ALBI grade, and resection margin status improves prognostic performance compared with TNM alone in patients undergoing curative resection for HCC. This model may support more accurate postoperative risk stratification.
- 7 May 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26
Open AccessIntegrated clinicopathological model versus TNM for predicting survival in resected hepatocellular carcinoma: a retrospective cohort study
Objective: To explore prognostic factors of postoperative hepatocellular carcinoma (HCC) and compare the prognostic performance of the tumor–node–metastasis (TNM) system with an integrated clinicopathological model. Methods: We conducted a cohort study evaluating 249 patients with HCC who underwent radical liver resection between January 2015 and December 2024. Overall survival (OS) was the primary endpoint. Independent prognostic factors were determined using the Cox proportional hazards model. Model performance was assessed using the correlation index (C-index) with bootstrap internal validation. Time-dependent receiver operating characteristic (ROC) curves, decision curve analysis (DCA), and calibration plots were used to assess discrimination, clinical utility, and agreement between predicted and observed outcomes. Results: In multivariable analysis, TNM stage, microvascular invasion (MVI), resection margin status, and albumin–bilirubin (ALBI) grade were independent predictors of OS. For recurrence-free survival (RFS), independent predictors included hepatitis status, ALBI grade, TNM stage, and MVI. The integrated model demonstrated improved discrimination compared with TNM alone, with a higher optimism-corrected C-index (0.676 vs. 0.647). Time-dependent ROC analysis showed significantly higher AUC values for the integrated model at 1 year (0.725 vs. 0.669, p = 0.046), 3 years (0.703 vs. 0.657, p = 0.024), and 5 years (0.684 vs. 0.649, p = 0.031). DCA indicated greater net benefit across clinically relevant thresholds, and calibration plots showed good agreement between predicted and observed survival probabilities. Conclusion: An integrated clinicopathological model incorporating TNM stage, MVI, ALBI grade, and resection margin status improves prognostic performance compared with TNM alone in patients undergoing curative resection for HCC. This model may support more accurate postoperative risk stratification.
- Open Access
- 1 May 2023
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 19, 425-433
Safety and Efficacy of Liver Venous Deprivation Following Transarterial Chemoembolization Before Major Hepatectomy for Hepatocellular Carcinoma
Objective: This study aimed to evaluate the safety and efficacy of liver venous deprivation (LVD) following transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). Methods: Between January 2021 and December 2022, HCC patients indicated for hepatectomy with initial insufficient future liver remnant (FLR) underwent LVD after TACE to induce preoperative liver hypertrophy. Results: Twenty-seven HCC patients with a median age of 55 years underwent LVD. No TACE or LVD procedure-associated complications occurred, except for 1 case presenting with grade A liver failure after LVD (then recovered after 7 days). The FLR volume was 29.3% (interquartile range [IQR] = 7.5) and 48.9% (IQR = 8.6) of the total liver volume before and after LVD, respectively (p < 0.001). The degree of hypertrophy and FLR hypertrophy rate were 14.8% (IQR = 8.4) and 55.2% (IQR = 36.7), respectively. All 27 patients demonstrated sufficient FLR after LVD (24 patients at three weeks post-LVD, one at six weeks, and two at ten weeks), but only 21 patients accepted surgery. Postoperative histopathology showed 16 patients with cirrhosis and five with mild fibrosis (F1, F2). One patient presented with severe intraoperative bleeding due to damage of left hepatic vein and developed grade C liver failure, then died on day 32 postoperation. Conclusion: LVD following TACE seems to be a safe, effective, and feasible method of inducing significant FLR regeneration in HCC, even in well-selected cirrhotic livers. Comparative studies with a large patient population and multicenter data are needed for further evaluation.
- 1 May 2023
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 19, 425-433
Open AccessSafety and Efficacy of Liver Venous Deprivation Following Transarterial Chemoembolization Before Major Hepatectomy for Hepatocellular Carcinoma
Objective: This study aimed to evaluate the safety and efficacy of liver venous deprivation (LVD) following transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). Methods: Between January 2021 and December 2022, HCC patients indicated for hepatectomy with initial insufficient future liver remnant (FLR) underwent LVD after TACE to induce preoperative liver hypertrophy. Results: Twenty-seven HCC patients with a median age of 55 years underwent LVD. No TACE or LVD procedure-associated complications occurred, except for 1 case presenting with grade A liver failure after LVD (then recovered after 7 days). The FLR volume was 29.3% (interquartile range [IQR] = 7.5) and 48.9% (IQR = 8.6) of the total liver volume before and after LVD, respectively (p < 0.001). The degree of hypertrophy and FLR hypertrophy rate were 14.8% (IQR = 8.4) and 55.2% (IQR = 36.7), respectively. All 27 patients demonstrated sufficient FLR after LVD (24 patients at three weeks post-LVD, one at six weeks, and two at ten weeks), but only 21 patients accepted surgery. Postoperative histopathology showed 16 patients with cirrhosis and five with mild fibrosis (F1, F2). One patient presented with severe intraoperative bleeding due to damage of left hepatic vein and developed grade C liver failure, then died on day 32 postoperation. Conclusion: LVD following TACE seems to be a safe, effective, and feasible method of inducing significant FLR regeneration in HCC, even in well-selected cirrhotic livers. Comparative studies with a large patient population and multicenter data are needed for further evaluation.